Condition

Hematologic Diseases

ClinicalTrials.gov condition label

Clinical trials11

Recruiting0

Common interventions17

Lead sponsors shown11

Clinical trials

11 shown

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient OutcomesNCT05443321 · 2022-11-01

ENROLLING_BY_INVITATION

National Project on Vaccines, COVID-19 and Frail PatientsNCT04848493 · 2021-04-19

Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During HospitalizationNCT05378139 · 2021-02-01

Data Collection of Standard Care and Evaluation of NHLBI Patients and DonorsNCT04450927 · 2020-06-16

ENROLLING_BY_INVITATION

Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator TrialNCT03342495 · 2018-02-06

Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical StudentsNCT03041571 · 2017-03-01

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeNCT02130882 · 2014-05-19

A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment OutcomesNCT01541631 · 2012-05-01

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)NCT00000623 · 2000-07-01

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast CancerNCT00001338 · 1993-06-01

Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus InfectionNCT00000587 · 1988-09-01

Common interventions

ArginineDRUG1 benralizumabDRUG1 COVID-19 vaccinesBIOLOGICAL1 DecitabineDRUG1 DeferiproneDRUG1 DeferoxamineDRUG1 erythropoietin, recombinantPROCEDURE1 FLAC chemotherapy with GM-CSFDRUG1 Health Information Exchange (HIE) platformOTHER1 Interview performed by MHP studentBEHAVIORAL1 Patient NavigatorOTHER1 Patient Provider Orientation ScaleBEHAVIORAL1 PlaceboOTHER1 Praziquantel and AlbendazoleDRUG1 SildenafilDRUG1 Usual CareOTHER1 Vital signs measurements with new appDEVICE1

Leading sponsors

Azienda USL Reggio Emilia - IRCCS1 Brigham and Women's Hospital1 Carelon Research1 Catholic University of Health and Allied Sciences1 National Cancer Institute (NCI)1 National Heart, Lung, and Blood Institute (NHLBI)1 National Institute of Allergy and Infectious Diseases (NIAID)1 Thomas Jefferson University1 University Hospital Bispebjerg and Frederiksberg1 University of Calgary1 University of Florida1

Trial status mix

COMPLETED5

UNKNOWN3

ENROLLING_BY_INVITATION2

WITHDRAWN1

Phase mix

NA3

PHASE22

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.